[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hcv\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hcv":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,48,77,100,128,159,190,212,235,263,291,324,349,370,388],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100580198","non-interventional-study-to-assess-the-number-of-people-with-untreatedunknown-hbv--hdv-and-hcv-in-south-east-austria-100580198",false,"NCT06834178","Non-interventional Study to Assess the Number of People With Untreated\u002FUnknown HBV + HDV and HCV in South-East Austria","Hepatitis Elimination And Liver Care in South-East Austria (HEAL-S)","HEAL-S","Inclusion Criteria:\n\n* The target population for the HCV cohort consists of individuals with detectable plasma HCV RNA at the latest observation.\n* The target population for the HBV cohort consists of individuals with detectable plasma HBV RNA at any time and no recorded HDV testing or a positive HDV serology.\n\nExclusion Criteria:\n\n* No valid SVRN (german: Sozialversicherungsnummer, english: Social insurance number)\n* No contact details available\n* Documented Sustained Virological Response (HCV cohort)\n* Documented assessment of HDV status (HBV cohort)","ALL",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The HEAL-S study is a non-interventional study with retrospective data analysis. It consists of two parts. First a retrospective analysis based on nucleic acid testing (NAT) results will be performed. Two cohorts (HCV) and (HBV) will be established. Patients falling into one (or both) of the two cohorts will be invited to a prospective linkage-to-care study. In this part, patients are invited to the clinic, where the possibility of hepatitis treatment will be discussed.",[24,25,26,27,28,29],"HBV","HCV","HDV","Coinfection","Hepatitis B Coinfection","Hepatitis B",[24,25,26,31,32,29,33,34],"Hepatitis B and D coinfection","untreated hepatitis","Hepatitis C","Hepatitis treatment","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-18","ACTUAL",{"date":41,"type":39},"2025-05-01",{"date":43,"type":20},"2026-10",{"name":45,"class":46},"Vanessa Stadlbauer-Koellner, MD","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100391550","appalachian-partnership-to-reduce-disparities-aim-2-100391550","NCT04378439","Appalachian Partnership to Reduce Disparities (Aim 2)","Harnessing the Power of Peer Navigation and mHealth to Reduce Health Disparities in Appalachia","Inclusion Criteria:\n\n* reside in one of the rural Appalachian catchment countiesreside in one of the rural Appalachian catchment counties\n* be ≥18 years of age\n* report being assigned male sex at birth and having had sex with at least 1 man in past 12 months\n* provide informed consent",true,"18 Years",{"count":58,"type":20},141,"INTERVENTIONAL",[61],"NA","By combining two strategies (i.e., peer navigation and mHealth) into a complete, culturally compatible, bilingual intervention to increase the use of needed HIV, STI, and HCV prevention and care services among racially\u002Fethnically diverse GBMSM and transgender women in rural Appalachia.\n\nStudy Investigators anticipate that participants in the intervention group, relative to counterparts in the delayed-intervention group, will demonstrate increased HIV, STI, and HCV testing.",[64,65,25],"HIV\u002FAIDS","STI",[67],"PrEP","2026-05-22",{"date":70,"type":39},"2026-05-26",{"date":72,"type":39},"2022-04-01",{"date":74,"type":20},"2027-05",{"name":76,"class":46},"Wake Forest University Health Sciences",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":85,"targetDuration":4,"studyType":59,"phases":87,"briefSummary":88,"conditions":89,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":47},"100463910","a-setting-focus-overdose-prevention-intervention-100463910","NCT05320835","A Setting Focus Overdose Prevention Intervention","A Geospatial Analysis of Hotspots and Targeted Injection Settings Pilot Intervention for HIV Prevention Among People Who Inject Drugs in Baltimore, Maryland","Oasis","Inclusion Criteria:\n\n* Current drug user (opioid use in the prior two weeks)\n\nExclusion Criteria:\n\n* Any mental or physical health impairment that impedes ability to participate",{"count":86,"type":20},285,[61],"A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).",[90,25,91],"HIV Infections","Drug Overdose","2026-05-19",{"date":68,"type":39},{"date":95,"type":39},"2022-04-30",{"date":97,"type":20},"2027-05-30",{"name":99,"class":46},"Johns Hopkins Bloomberg School of Public Health",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":59,"phases":109,"briefSummary":110,"conditions":111,"keywords":114,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":47},"100595343","hivhbvhcv-triple-screening-in-primary-care-100595343","NCT07031219","HIV\u002FHBV\u002FHCV Triple Screening in Primary Care","Syndemic Triple HIV\u002FHBV\u002FHCV Virus Screening Via EMR Automation at Primary Care Clinics","Inclusion Criteria:\n\n* Outpatient primary care adult providers at participating institutions\n* Providers who provide consent to participate in this study.\n* Providers must intend to continue their current practice for at least 12 months.\n* Providers with at least 12 months experience in their current practice.\n\nExclusion Criteria:\n\n* Providers who do not consent to participate\n* Sub-specialty providers\n* Pediatric providers\n* Providers who anticipate leaving their current practice within the next 12 months (i.e. providers who plan to retire, move, etc.).\n* Providers with less than 12 months experience in their current practice (i.e. new providers or trainees who joined the practice within the last year)\n* Note: family medicine and med\u002Fpeds providers can participate, but only for their adult patients. The intervention alert+order panel and any data collection will be restricted to adult patients ≥ 18 years old.",{"count":108,"type":20},50,[61],"Design:\n\nThis will be a within-subjects repeated-measures design, testing an electronic medical record pop-up alert linked to order panels for screening blood tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Study participants will be primary care providers. For each participating provider, their encounter will be randomized to either control (no alert; no changes to EMR interface) or an alert with triple-testing order panel intervention arm (alert linked to order panel with screening tests for all three bloodborne viruses (BBVs) selected by default; the alert will be triggered when a provider attempts to order a screening test for at least one BBV). The alert linked to triple testing orders will only be triggered if the provider orders a virus BBV screening test based on their normal practice and standard of care for their patient. Providers will see which orders are selected prior to signing (finalizing) them; therefore, this study will be unblinded. To mitigate the effect of unblinding, randomization will occur at the encounter level which will lead to providers experiencing both the control and intervention conditions randomly throughout the duration of the study.\n\nOutcomes\u002Fendpoints:\n\nThe investigators will compare incidences of HIV, HBV, and HCV diagnoses between the two encounter conditions, estimate number of cases missed by not triple-testing, estimate laboratory costs per condition, and measure patient encounters per condition.",[112,113,25],"HIV","HBV (Hepatitis B Virus)",[115,116,117],"screening","provider orders","quality improvement","NOT_YET_RECRUITING","2026-04-27",{"date":121,"type":39},"2026-04-29",{"date":123,"type":20},"2026-06-01",{"date":125,"type":20},"2027-06",{"name":127,"class":46},"University of Texas Southwestern Medical Center",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":55,"sex":17,"minAge":136,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":139,"conditions":140,"keywords":145,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":4},"100632686","evaluation-of-free-sti-testing-pilot-projects-in-lucerne-and-zurich-switzerland-100632686","NCT07516912","Evaluation of Free STI Testing Pilot Projects in Lucerne and Zurich, Switzerland","feSTI: Evaluation of Free HIV and STI Testing and Counselling Services for Young and Disadvantaged Populations in Lucerne and Zurich","feSTI","Inclusion Criteria:\n\n* taking part in the pilot programmes\n* understand the study information\n* 16 years of age or older\n\nExclusion Criteria:\n\n* not eligible for the pilot programmes\n* not understanding the study information\n* less than 16 years old","16 Years",{"count":138,"type":20},1800,"The main goal of the observational study is to evaluate participants' satisfaction with free HIV and sexually transmitted infection (STI) testing and counselling offered by the cities of Lucerne and Zurich, Switzerland to young people and people with low incomes. Counselling and testing can be accessed without participating in the study arm of the project.",[141,142,143,144,25],"HIV (Human Immunodeficiency Virus)","Chlamydia","Gonorrhea","Syphilis",[146,147,112,148,149],"Voluntary counselling and testing","sexually transmitted infections","implementation of free testing","barriers to care","2026-04-02",{"date":152,"type":39},"2026-04-08",{"date":154,"type":20},"2026-04-07",{"date":156,"type":20},"2029-02-28",{"name":158,"class":46},"University of Zurich",{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":169,"conditions":170,"keywords":177,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100625994","changes-in-bile-acids-and-microbiota-in-patients-with-hepatitis-d-treated-with-bulvertide-100625994","NCT07429864","Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide","Changes in Bile Acid Profile and Gut Microbiota in Patients Undergoing Treatment With Bulevirtide for Hepatitis Delta Virus Infection","Bio-Delta","Inclusion Criteria:\n\n* Patients with chronic HDV-related hepatitis or compensated liver cirrhosis (Child-Pugh class A)\n* Positive HDV RNA within the 24 weeks prior to enrollment\n* Ongoing antiviral therapy for HBV at the time of enrollment\n* First prescription of Bulevirtide 2 mg issued within 30 days prior to enrollment\n* Caucasian ethnicity\n* Age ≥18 years\n* Normocaloric omnivorous diet\n* No intake of antibiotics, probiotics, or prebiotics in the month prior to enrollment\n* Signed informed consent\n\nExclusion Criteria:\n\n* Decompensated liver cirrhosis (Child-Pugh Score B or C)\n* Patients without HBV-HDV-related infection\u002Fhepatitis\u002Fcirrhosis\n* Age ≤18 years\n* Pregnant or breastfeeding women\n* Concomitant diseases with short life expectancy (solid or hematologic neoplasms, heart failure NYHA III\u002FIV, COPD GOLD C-D)\n* Conditions (celiac disease, chronic inflammatory bowel diseases) or use of medications (antibiotics, probiotics, prebiotics) capable of altering gut microbiota composition",{"count":168,"type":20},20,"HDV is an RNA virus that infects only in the presence of HBV, affecting about 13% of HBsAg carriers. In Italy, prevalence ranges from 3.2% to 9.3%. It increases the risk of cirrhosis, fulminant hepatitis, and HCC, particularly in high-risk groups (HIV, HCV, drug users, dialysis patients). Until 2020, pegIFN was the only therapy; since 2022, bulevirtide (BLV) has been available, blocking viral entry into hepatocytes and reducing HDV RNA and liver stiffness, with efficacy in 45-48% of patients, though the optimal treatment duration remains uncertain. The gut microbiota and bile acids also play a role in fibrosis and cirrhosis progression: dysbiosis, typical in cirrhotic patients, alters bile acid metabolism and increases intrahepatic toxicity.",[24,171,25,90,172,173,174,175,176],"HBV Coinfection","Hepatocellular Carcinoma","Cirrhosis, Liver","Fibrosis, Liver","Bile Acid Malabsorption","Microbial Colonization",[178,179,180],"gut microbiota","Bile Acids","dysbiosis","2026-02-17",{"date":183,"type":39},"2026-02-24",{"date":185,"type":39},"2025-09-24",{"date":187,"type":20},"2027-10",{"name":189,"class":46},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":191,"slug":192,"hasResults":11,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":196,"eligibilityCriteria":197,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":198,"targetDuration":4,"studyType":59,"phases":200,"briefSummary":201,"conditions":202,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100489447","prophylaxis-with-direct-acting-antivirals-for-kidney-transplantation-from-hcv-infected-donors-to-uninfected-recipients-100489447","NCT05653232","Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients","Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From Hepatitis C Virus-Infected Donors to Uninfected Recipients: a Randomized Controlled Trial","PREVENT-HCV","Inclusion Criteria:\n\n* Participant meets the standard criteria for KT at local center.\n* Participant is able to understand and provide informed consent.\n* Participant is ≥ 18 years old.\n\nExclusion Criteria:\n\n* Participant has active HCV infection (detectable HCV RNA) at time of screening.\n* Participant has cirrhosis or advanced liver fibrosis.\n* Participant's aspartate aminotransferase (AST) or ALT \\> 2.5 times the upper limit of normal (ULN), within 60 days of screen.\n* Participant has human immunodeficiency virus infection (HIV), or active hepatitis B (HBV) infection.\n* Participant is unable to safely substitute or discontinue a medication that is contraindicated with the study medication.\n* Past or current medical problems, which may pose additional risks from participation in the study, interfere with the participant's ability to comply with study, or impact the quality of the data obtained from the study.\n* Participant is pregnant or breastfeeding.",{"count":199,"type":20},120,[61],"This study is being done to find out the best time to start medication for Hepatitis C Virus (HCV) in HCV-negative recipients of HCV-positive (HCV D+\u002FR-) kidney transplants. Participants will be randomized into one of two groups:\n\nArm 1 - Prophylaxis: This group will start the HCV medication before transplant and will take a shorter course of HCV medication for 2 weeks.\n\nArm 2 - Transmit and Treat: This group will start the HCV medication after transplant and will take the full course (12 weeks) of HCV medication.",[25],"2026-02-13",{"date":181,"type":39},{"date":206,"type":39},"2023-04-19",{"date":208,"type":20},"2027-03",{"name":210,"class":46},"Johns Hopkins University",9,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":219,"targetDuration":221,"studyType":21,"phases":4,"briefSummary":222,"conditions":223,"keywords":224,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100553235","facilitated-telemedicine-in-the-catholic-health-system-100553235","NCT06483451","Facilitated Telemedicine in the Catholic Health System","Hepatitis C Virus Management Through Facilitated Telemedicine Integrated Into Opioid Treatment Programs: Catholic Health System Experience","Inclusion Criteria:\n\n* evidence of active HCV infection\n\nExclusion Criteria:\n\n* no evidence of active HCV infection",{"count":220,"type":20},200,"2 Years","Hepatitis C virus is a leading cause of morbidity and mortality globally with the highest prevalence and incidence among people with opioid use disorder. We aim to establish facilitated telemedicine as a standard of care treatment approach at 3 opioid treatment programs operated by the Catholic Health System. This study is a chart review data analysis to evaluate outcomes of facilitated telemedicine integrated into opioid treatment programs and to evaluate the number of individuals who initiate and complete treatment for hepatitis C virus infection.",[25],[225],"telemedicine","2026-02-03",{"date":228,"type":39},"2026-02-05",{"date":230,"type":20},"2026-07",{"date":232,"type":20},"2026-12",{"name":234,"class":46},"State University of New York at Buffalo",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":243,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":245,"conditions":246,"keywords":249,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":262},"100606069","clinical-performance-evaluation-of-magia-ivd-md-multiplex-testing-hivhbvhcvsyphilis-100606069","NCT07170748","Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV\u002FHBV\u002FHCV\u002FSyphilis)","Clinical Performance Evaluation of MagIA In-vitro Diagnostic Medical Device for Multiplex Screening of Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C and Syphilis in Sub-Saharan Africa","MAGICS IBCS","Inclusion Criteria:\n\n* Provide informed consent for participation in this study.\n* Patient sample must meet at least one of the criteria below:\n\n  1\\. Positive samples (serum or plasma) from individuals who meet at least one of the following conditions:\n* HIV-1 Ab positive\n* HIV-2 Ab positive\n* HCV-Ab positive\n* HBsAg positive\n* Positive for at least TPHA, with those positive for both TPHA and VDRL ideally included 2. Negative samples (serum or plasma) from individuals who meet at least one of the following conditions:\n* Blood donors\n* Hospitalized patients or individuals coming to the clinic\n* Vulnerable populations (such as: drug users, prison population, ...) 3. Negative samples (serum or plasma) containing potential interfering substances from individuals who meet at least one of the following conditions:\n* Being a pregnant woman\n* Infected with at least one of the following viruses or bacteria: hepatitis A virus (HAV), hepatitis E virus (HEV), tuberculosis (TB), gonorrhoea, chlamydia, influenza virus, Covid-19\n* Presenting any of the following criteria:\n\n  * High IgG levels\n  * High rheumatoid factor (\\>15 IU\u002FmL)\n  * High cholesterol levels (\\>0.24 md\u002FdL)\n  * High bilirubin levels (\\>0.25 mg\u002FmL)\n  * High triglyceride levels (\\>500 mg\u002FdL)\n  * Diagnosis of cancer\n\nExclusion Criteria:\n\n* Samples from patients below 18 years of age",{"count":244,"type":20},2950,"Performance study to evaluate the clinical performance of the In-Vitro Diagnostics Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from serum, plasma samples collected prospectively or retrospectively in Ivory Coast and Kenya.",[247,112,24,25,144,248],"Multiplex Testing of HIV, HBV, HCV and Syphilis","Point of Care Testing",[250,112,24,25,144,251],"point of care test","multiplex testing","2026-01-30",{"date":254,"type":39},"2026-02-02",{"date":256,"type":39},"2025-07-29",{"date":258,"type":20},"2026-04",{"name":260,"class":261},"MagIA Diagnostics","INDUSTRY",2,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":55,"sex":270,"minAge":56,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":59,"phases":273,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":47},"100613284","hivstihcv-testing-and-overdose-prevention-among-survivors-of-sex-trafficking-100613284","NCT07264582","HIV\u002FSTI\u002FHCV Testing and Overdose Prevention Among Survivors of Sex Trafficking","A Citizen Science Approach to Increase HIV\u002FSTI\u002FHCV Testing and Substance Use Service Utilization Among Survivors of Sex Trafficking Living in New York City","Inclusion Criteria:\n\n* 18 years or older\n* Born biologically female or identify as a woman\n* Living in New York City\n* Used illicit substances within the past 12 months or has a history of substance use dependency\n* Would feel safe participating in the study\n* Is a survivor of sex trafficking as defined by the following criteria: 1) Has the individual ever had sex for things of value? If 'Yes', then the individual must also answer 'Yes' to the following question, 2) Was the individual pressured or forced by another person to do this?\n\nExclusion Criteria:\n\n* Not willing to provide consent or not able to understand study procedures","FEMALE",{"count":272,"type":20},368,[61],"This project will assess whether a digital survivor crowdsourced intervention can increase HIV\u002FSTI\u002FHCV testing and overdose prevention kit utilization among survivors of sex trafficking living in New York City. Survivors of sex trafficking have among the highest rates of HIV\u002FSTIs\u002FHCV and substance use disorder (SUD), yet they face substantial barriers to care, including lack of information about care and financial and logistical constraints. In addition, there is a lack of public health messaging tailored specifically for survivors of sex trafficking to meet their needs. Citizen science approaches, such as crowdsourcing (i.e., engaging groups of individuals to address public health challenges and share solutions), are scalable, cost-effective tools that can increase HIV\u002FSUD prevention and treatment utilization. Crowdsourcing can be used to engage survivors in developing tailored messaging to promote HIV\u002FSTI\u002FHCV testing, overdose prevention, and treatment utilization. Complementing crowdsourcing, specimen self-collection with remote HIV\u002FSTI\u002FHCV testing and online delivery of overdose prevention kits to survivors may also increase use of needed healthcare services. Study aims are: 1) develop crowdsourced digital messages to promote HIV\u002FSTI\u002FHCV testing uptake and utilization of overdose prevention services for substance use among sex trafficking survivors; 2) in a randomized controlled trial, to compare the survivor-crowdsourced HIV and substance use intervention to existing public health messaging among sex trafficking survivors (n=368) in New York City; and 3) assess the contribution of multi-level factors on reach, effectiveness, adoption, implementation, and maintenance (RE-AIM) outcomes. This work will result in a digital crowdsourced intervention to increase HIV\u002FSTI\u002FHCV testing uptake, overdose prevention kit utilization, and linkage to care among survivors of sex trafficking. This project will also result in a crowdsourcing and messaging toolkit that can be broadly distributed to public health and other agencies across the country for their use in designing messaging campaigns for survivors. Findings from this project will lay the groundwork for citizen science-developed HIV and SUD interventions for sex trafficking survivors across the US.",[276,65,25,277],"HIV Testing","Overdose, Drug",[112,65,25,279,280,281],"overdose prevention","crowdsourcing","citizen science","2026-01-27",{"date":284,"type":39},"2026-01-28",{"date":286,"type":20},"2026-10-01",{"date":288,"type":20},"2028-06-30",{"name":290,"class":46},"Columbia University",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":299,"targetDuration":301,"studyType":21,"phases":4,"briefSummary":302,"conditions":303,"keywords":305,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":323},"100600261","scaling-up-point-of-care-hepatitis-c-testing-and-treatment-in-canada-100600261","NCT07095192","Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada","Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada: A Multilevel Implementation Science Study of Clinical Processes, Barriers, Facilitators and Implementation Strategies","SCALE POCT","Inclusion Criteria:\n\n* Individuals aged ≥18 years who have a risk factor for HCV acquisition or are attending a site that provides services to people with an HCV acquisition risk.\n* Service providers and managers who are currently employed at a site providing HCV-related services, involved in or supervising the delivery of HCV-related services.\n* Policymaker must hold a position in local, provincial, or national government or a health authority that influences HCV testing\u002Ftreatment policies and be able to provide insights into the strategic planning and funding for HCV care.\n* Laboratory and quality assurance stakeholders must hold a role in laboratory services, quality assurance, or regulatory oversight of point-of-care testing at the provincial, national, or organizational level.\n\nExclusion Criteria:\n\n* Younger than 18 years old",{"count":300,"type":20},300,"1 Month","The SCALE-POCT study is a national initiative designed to provide robust evidence for scaling up point-of-care hepatitis C testing for key populations. The study seeks to map current hepatitis C clinical processes, identify barriers and facilitators to implementation, and co-design practical tools and strategies in partnership with stakeholders.\n\nA major obstacle to hepatitis C elimination and increasing treatment uptake is the current multi-step diagnostic process, which leads to loss to follow-up and treatment delays, particularly among high-risk groups such as people who inject drugs. Point of-care hepatitis C antibody tests (results: 5-20 mins) and RNA tests (results: 60 mins), could enable single-visit diagnosis, reducing loss to follow-up. However, integrating these tests into key settings presents challenges. The overarching goal of this study is to generate evidence to inform the scale-up point-of-care hepatitis C testing and treatment in key settings in Canada. This study is observational in nature and does not involve the direct implementation of point-of-care hepatitis C testing. Instead, it aims to understand the contextual, procedural, and operational factors that would support its successful adoption and sustainability. By examining existing care models and engaging with key stakeholders, the study seeks to build a foundation for future implementation efforts. Specific objectives include:\n\n1. Map current hepatitis C care processes and explore how point-of-care testing could fit into these models;\n2. Identify barriers and facilitators to implementing point-of-care hepatitis C testing across settings and provinces;\n3. Co-design tools and strategies (such as training guides, standard procedures) to support point-of-care testing;\n4. Assess feasibility, acceptability, and costs of the co-designed tools and strategies.",[25,304],"HEPATITIS C VIRUS CHRONIC INFECTION",[25,306,307,308,309,310,311,312,313],"Hepatitis C Virus Chronic Infection","Rapid point-of-care testing","Implementation science","Knowledge translation","Marginalized populations","Infectious diseases","Barriers and facilitators","Implementation strategies","2025-07-23",{"date":316,"type":39},"2025-07-31",{"date":318,"type":39},"2025-05-20",{"date":320,"type":20},"2028-09-20",{"name":322,"class":46},"McGill University",12,{"id":325,"slug":326,"hasResults":11,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":330,"eligibilityCriteria":331,"healthyVolunteers":55,"sex":17,"minAge":332,"maxAge":333,"enrollmentInfo":334,"targetDuration":4,"studyType":59,"phases":336,"briefSummary":337,"conditions":338,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":340,"lastUpdatePostDateStruct":341,"startDateStruct":343,"completionDateStruct":345,"leadSponsor":347,"locationsCount":47},"100556708","tools-to-identify-people-at-risk-or-already-infected-with-hiv-and-hcv-100556708","NCT06528626","Tools to Identify People At Risk or Already Infected with HIV and HCV","Wedge-Shaped Clusterded Randomizad Trial to Evaluate Two Tools to Identify People At Risk or Already Infected with HIV and HCV","ATENEA","Inclusion Criteria:\n\n\\- 14-65 years in the health area or who are captured for inclusion by health personnel. They give their consent to participate.\n\nExclusion Criteria:\n\n* Having already been included in the study, not signing the consent.","14 Years","65 Years",{"count":335,"type":20},240000,[61],"Wedge-Shaped Clusterded Randomizad Trial to Evaluate Two Tools to identify People at Risk or already Infected with HIV and HCV",[64,339,25],"STD","2025-02-27",{"date":342,"type":39},"2025-03-03",{"date":344,"type":39},"2023-07-01",{"date":346,"type":20},"2025-12-01",{"name":348,"class":46},"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal",{"id":350,"slug":351,"hasResults":11,"nctId":352,"briefTitle":353,"officialTitle":354,"acronym":4,"eligibilityCriteria":355,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":356,"enrollmentInfo":357,"targetDuration":4,"studyType":59,"phases":359,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":362,"lastUpdatePostDateStruct":363,"startDateStruct":365,"completionDateStruct":367,"leadSponsor":368,"locationsCount":4},"100562516","innovate-involve-inspire-100562516","NCT06604182","Innovate, Involve, Inspire","Community-based HCV Testing and Treatment of People Who Inject Drugs: Innovate, Involve, Inspire","Inclusion Criteria:\n\n* Drug use in the past 90 days\n* Age 18 and above\n* Positive for HCV RNA\n\nExclusion Criteria:\n\n* No meeting inclusion criteria\n* Pregnancy","60 Years",{"count":358,"type":20},1454,[61],"The study will test a Community-based Simplified HCV Testing and Treatment Algorithm (CBSA), implemented at community harm reduction fixed or mobile sites.\n\nAll potential participants with positive anti-HCV test will undergo diagnostic procedures including HCV-RNA testing. Those eligible for CBSA will be prescribed a fixed dose combination tablet: sofosbuvir\u002Fdaclatasvir.\n\nSustained virologic response (SVR) will be assessed 12 weeks after treatment completion. All those who achieve SVR will be tested for HCV\\_RNA at six and 12 months after SVR12.",[25],"2024-09-17",{"date":364,"type":39},"2024-09-19",{"date":366,"type":20},"2025-01",{"date":230,"type":20},{"name":369,"class":46},"Frontline AIDS",{"id":371,"slug":372,"hasResults":11,"nctId":373,"briefTitle":374,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":4},"100560604","current-situation-of-health-care-in-women-with-hbv-or-hcv-infection-100560604","NCT06579313","Current Situation of Health Care in Women With HBV or HCV Infection","Inclusion Criteria:\n\nHBV Cohort -\n\n* ≥18 years old\n* serum HBsAg positive for \\>6 months\n* Treatment naïve or,\n* Patients who had been previously treated for HBV but discontinued for at least 1 year before enrollment\n\nHCV Cohort -\n\n* ≥18 years old\n* HCV-Ab positive\n* HCV RNA positive\n* Treatment naïve or,\n* Patients who had been previously treated for HCV with a regimen containing interferon and not had a sustained virologic response.\n\nExclusion Criteria:\n\n* HBV\u002FHCV Co-infection\n* HIV\n* History of hepatic decompensation or hepatocellular carcinoma\n* Other carcinoma\n* Other severe liver disease\n* Severe Comorbidity like cardiovascular disease, diabetes etc.\n* Patients who had discontinued previous HCV treatment because of an adverse event.\n* Patients who had previously received any nucleotide analogue HCV NS5B inhibitor or any NS5A inhibitor\n* Patients who had discontinued previous HBV treatment because of an adverse event.",{"count":377,"type":20},2500,"A multicenter, retrospective study conducted in male and female population infected with HBV or HCV in east China. HCV part, study will enroll 500 HCV antibody positive and HCV RNA positive patients during 2020.7-2023.12 and then observe the characteristics, duration from diagnosis to treatment, treatment rate and sustained virologic response (SVR12) among eligible female and male patients. HBV part, study will enroll 2000 HBsAg positive patients during 2016.7-2019.12 and then observe the clinical characteristics, natural history, duration from diagnosis to treatment, treatment rate and adherence among eligible female and male patients.",[24,25],"2024-08-29",{"date":382,"type":39},"2024-08-30",{"date":384,"type":20},"2024-09-01",{"date":316,"type":20},{"name":387,"class":46},"Ruijin Hospital",{"id":389,"slug":390,"hasResults":11,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":394,"eligibilityCriteria":395,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":396,"enrollmentInfo":397,"targetDuration":4,"studyType":59,"phases":399,"briefSummary":401,"conditions":402,"keywords":4,"overallStatus":118,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":47},"100485186","phase-2-nivolumabipilimumab-and-chemotherapy-combination-in-advanced-nsclc-patients-with-hiv-hbv-hcv-and-long-covid-syndrome-100485186","NCT05597800","Nivolumab\u002FIpilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome","A Phase 2, Multicenter, Open Label, Clinical Trial Evaluating Safety and Activity of Nivolumab\u002FIpilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Post-acute Sequelae of SARS-CoV2 Infection (PASC).","LUNGVIR","Inclusion Criteria:\n\n* Participants must have histologically confirmed diagnosis of metastatic or unresectable NSCLC;\n* No sensitizing EGFR, ALK, ROS1, BRAF and NTRK alterations;\n* Eastern Cooperative Oncology Group (ECOG) score 0-1 (physically able to carry out light housework or office work through to being fully active as they were before cancer);\n* No prior systemic anticancer therapy;\n* Tissue or Programmed death-ligand 1 (PD-L1) results available;\n* HIV-1 or HIV-2 chronic infection, defined as i) a positive HIV 1-2 western blot or other FDA\u002FCE approved HIV confirmatory test (regardless the results of the HIV 1-2 screening test used \\[2nd, 3rd, 4th generation tests, rapid tests or laboratory tests (i.e., ELISA, EIA, CLIA, etc.)\\], ii) the referring physician's written record that HIV infection was documented, with supporting information on the participant's relevant medical history and\u002For current antiretroviral treatment for HIV infection;\n* Only subjects with chronic or resolved HBV infections might be eligible. Chronic HBV infections is defined as: the persistence of HBsAg positivity for more than 6 months (regardless HBeAg result, HBV-DNA level and the presence of liver necroinflammation). Resolved HBV infection is defined by: the absence of liver inflammation (clinically and laboratory), HBsAg negativity and HBsAb (anti-HBs antibodies) and HBcAb (anti-HBc IgG) positive result;\n* Only subjects with resolved HCV infections might be eligible. Subjects with a newly diagnosed chronic HCV infection (defined as: positive HCV antibodies + detectable HCV-RNA) should be treated for HCV infection before enrollment. Acute HCV infection \\[defined as a positive HCV-RNA and i) a negative serological HCV assay (HCV-Ab) or ii) a positive serological HCV assay (HCV-Ab) with a negative test 6 months earlier\\] cannot be enrolled in the study.\n* Patients with past HCV infection, with no evidence of chronic infection (i.e., anti-HCV antibody positivity, HCV-RNA negativity) should be excluded;\n* Patients with confirmed Long Covid syndrome or PASC defined, as suggest by World Health Organization (WHO), as \"condition occurs in individuals with a history of probable or confirmed SARS CoV-2 infection, usually 3 months from the onset of COVID-19 with symptoms and that last for at least 2 months and cannot be explained by an alternative diagnosis\". This condition must be present at enrollment;\n* Participants must have a nasopharyngeal swab positive for Sars-Cov2 within 12 months before enrolment;\n* Participants must be either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent) for at least 2 weeks prior to first treatment;\n* Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam; scans must have been performed within 4 weeks prior to registration.\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) within 24 hours prior to the start of study drug;\n* Ability to understand and to sign a written informed consent document.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) score ≥2;\n* Untreated symptomatic brain metastases or leptomeningeal metastases;\n* Another active concomitant malignancy;\n* Active, known or suspected, autoimmune disease;\n* Active HBV or HCV infection, presence of any infectious disease requiring specific treatment.\n* Active Sars-Cov2 infection.","75 Years",{"count":398,"type":20},105,[400],"PHASE2","Study type: Phase 2 - Interventional Trial Number of patients to be enrolled: 105 Participating countries: Italy Study drugs: nivolumab and ipilimumab Cohort A: HBV and HCV patients Cohort B: HIV patients Cohort C: Long COVID syndrome The stratification factors are HBV\u002FHCV positive (cohort A), HIV positive (cohort B), patients with Long Covid syndrome (Cohort C), histology (squamous vs non-squamous histology), and gender (male vs female).",[403,112,24,25,404],"NSCLC Stage IV","Long COVID","2022-10-26",{"date":407,"type":39},"2022-10-28",{"date":409,"type":20},"2023-02-01",{"date":411,"type":20},"2027-03-30",{"name":413,"class":46},"Universita di Verona"]